Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM AMINOSALICYLATE versus SODIUM AMINOSALICYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM AMINOSALICYLATE versus SODIUM AMINOSALICYLATE.
POTASSIUM AMINOSALICYLATE vs SODIUM AMINOSALICYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exact mechanism unknown; may competitively inhibit folic acid synthesis and/or disrupt mycobacterial cell wall metabolism via inhibition of salicylate hydroxylation.
Sodium aminosalicylate inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking bacterial growth.
Adults: 4 g (as granules or powder) orally twice daily, equivalent to 8 g/day of aminosalicylic acid base.
4 g orally three times daily (total daily dose 12 g) for tuberculosis treatment. Also available as 10 g in 250 mL for intravenous infusion over 5-6 hours, typically once daily.
None Documented
None Documented
0.5-1.5 hours for parent drug; acetylated metabolite half-life 2-3 hours; accumulation occurs in renal impairment.
0.75-1.5 hours (parent drug); prolongs to 4-6 hours in renal impairment or with probenecid coadministration. Rapid acetylation phenotype reduces half-life by ~30%.
Renal: >80% as metabolites (acetyl, glycolyl conjugates) and unchanged drug; fecal: <5%.
Renal: >80% as metabolites (acetylated and free), with 50-60% as N-acetyl-4-aminosalicylic acid; biliary/fecal: <1%.
Category C
Category C
Antitubercular Agent
Antitubercular Agent